Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director · President and CEO | May 15, 2026 | May 19, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,008 |
Last balance in matching sequence
After 2026-05-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 128,497 · Balance 1,486,055 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025. F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2026-05-18 · Gift · Disposed 124,047 · Balance 1,362,008 F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,004,327 |
Reported balance
After 2026-05-18 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-05-18 · Gift · Acquired 124,047 · Balance 2,004,327 F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. F4: Shares of Common Stock held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 17,728 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 17,728 F5: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025.
F2: Includes 1,362,008 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock.
F3: On May 18, 2026, the Reporting Person gifted 124,047 shares of Common Stock to Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.
F4: Shares of Common Stock held by Michael M. Morrissey and Meghan D. Morrissey, Trustees of the Morrissey Family Living Trust dated July 21, 1994, as amended.
F5: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2019 Filed Dec 7, 2019 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 9,788 | $17.67 | $172,953.96 |
DisclosureSEC source: 0000939767-19-000199 · wf-form4_157567744721462.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,114 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 4, 2019. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 37,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000199 · wf-form4_157567744721462.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,902 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 37,181 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that Exelixis, Inc. has achieved a net product revenue target over four consecutive fiscal quarters; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 4, 2019, the Committee convened to determine that the net product revenue target over four consecutive fiscal quarters had been achieved during the three months ended September 27, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 85,985 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:34 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 7,898 | $16.51 | $130,395.98 |
DisclosureSEC source: 0000939767-19-000194 · wf-form4_157387164772707.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,721 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded September 26, 2016. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 02:34 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 10,530 | $16.51 | $173,850.30 |
DisclosureSEC source: 0000939767-19-000194 · wf-form4_157387164772707.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,619 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded October 3, 2017. F2 · balance_after: Includes 67,394 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 02, 2019 Filed Oct 5, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 35,409 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000179 · wf-form4_157023373638520.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,409 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| October 02, 2019 Filed Oct 5, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 26,364 | $17.66 | $465,588.24 |
DisclosureSEC source: 0000939767-19-000179 · wf-form4_157023373638520.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,149 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligation, broker commission and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.47 to $17.95. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| October 02, 2019 Filed Oct 5, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 35,409 | $7.18 | $254,236.62 |
DisclosureSEC source: 0000939767-19-000179 · wf-form4_157023373638520.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 102,394 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 18, 2019 Filed Sep 21, 2019 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000174 · wf-form4_156902433469283.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,00 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| September 18, 2019 Filed Sep 21, 2019 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 37,227 | $19.20 | $714,758.40 |
DisclosureSEC source: 0000939767-19-000174 · wf-form4_156902433469283.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,104 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligation, broker commission and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.05 to $19.38. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| September 18, 2019 Filed Sep 21, 2019 00:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000174 · wf-form4_156902433469283.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 102,394 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 6,526 | $19.26 | $125,690.76 |
DisclosureSEC source: 0000939767-19-000171 · wf-form4_156842190477356.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,331 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 12, 2019. Read SEC document |
| September 12, 2019 Filed Sep 14, 2019 00:45 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 24,788 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000171 · wf-form4_156842190477356.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,857 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 24,788 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Compensation Committee's certification that Exelixis, Inc. has achieved a quarterly net product revenue target; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 12, 2019, the Committee convened to determine that the quarterly net product revenue target had been achieved during the three months ended June 28, 2019, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2020, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 102,394 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $7.18 Strike: $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000163 · wf-form4_156600011369863.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 35,040 | $20.11 | $704,654.40 |
DisclosureSEC source: 0000939767-19-000163 · wf-form4_156600011369863.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,069 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligation, broker commission and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.29. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000163 · wf-form4_156600011369863.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 02, 2019 Filed Aug 3, 2019 00:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $7.18 Strike: $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000159 · wf-form4_156479213345382.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| August 02, 2019 Filed Aug 3, 2019 00:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 35,040 | $20.25 | $709,560.00 |
DisclosureSEC source: 0000939767-19-000159 · wf-form4_156479213345382.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,109 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligations, broker commissions and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.08 to $20.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| August 02, 2019 Filed Aug 3, 2019 00:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000159 · wf-form4_156479213345382.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000148 · wf-form4_156358103780148.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 34,721 | $21.37 | $741,987.77 |
DisclosureSEC source: 0000939767-19-000148 · wf-form4_156358103780148.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,149 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligations, broker commissions and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.26 to $21.49. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| July 17, 2019 Filed Jul 20, 2019 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000148 · wf-form4_156358103780148.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 34,721 | $21.03 | $730,182.63 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,870 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligations, broker commissions and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.92 to $21.24. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 29, 2019 Filed May 31, 2019 00:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 14,591 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000137 · wf-form4_155926401044302.xml · derivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,409 Underlying: Common Stock · 14,591 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| May 29, 2019 Filed May 31, 2019 00:53 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 14,591 | $7.18 | $104,763.38 |
DisclosureSEC source: 0000939767-19-000137 · wf-form4_155926401044302.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 42,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 42,000 | $20.15 | $846,300.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.27. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 42,000 | $5.56 | $233,520.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $20.75 | $830,000.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.19. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 24, 2019 Filed Apr 27, 2019 00:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000099 · wf-form4_155632406024567.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $24.06 | $962,400.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.69 to $24.24. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 23:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000092 · wf-form4_155511335543491.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $23.39 | $935,600.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.08 to $23.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 23:41 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000075 · wf-form4_155390288826665.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 28,367 | $24.80 | $703,501.60 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.68 to $24.98. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 11,633 | $24.24 | $281,983.92 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,367 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.68 to $24.67. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 16, 2019 00:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000063 · wf-form4_155269485960427.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 40,000 | $22.69 | $907,600.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.08 to $22.98. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 200 | $22.66 | $4,532.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.65 to $22.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 39,800 | $22.39 | $891,122.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,200 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.65 to $22.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:58 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000016 · wf-form4_154906911161318.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.